Improvement in inner retinal function in glaucoma in response to nicotinamide (Vitamin B3) supplementation: a crossover randomized clinical trial

Abstract

Importance Retinal ganglion cells endure significant metabolic stress in glaucoma but maintain capacity to recover function. Nicotinamide, a precursor of NAD + , is low in serum of glaucoma patients and its supplementation provides robust protection of retinal ganglion cells in preclinical models. However, the potential of nicotinamide in human glaucoma is unknown. Background To determine whether nicotinamide supplementation alongside conventional IOP-lowering therapy improves retinal ganglion cell function in glaucoma. Design Crossover, double-masked, randomised clinical trial. Participants recruited from two tertiary care centres. Participants Fifty-seven participants, diagnosed and treate..